Gold prices bounce off 3-week lows; demand likely longer term
Khalifa Sammy, the Chief Technology Officer of Vicarious Surgical Inc. (NYSE:RBOT), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Sammy sold 239 shares of Class A Common Stock on June 3, 2025. The shares were sold at a weighted average price of $7.2509, with individual trades ranging from $7.01 to $7.52 per share. The total value of the transaction was approximately $1,732. The sale comes amid challenging market conditions for RBOT, with the stock down about 56% over the past six months and currently trading at $7.75, significantly below its 52-week high of $19.InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $8.50 and $13.
This sale was conducted to cover tax obligations related to the vesting of restricted stock units granted on June 2, 2023. Following the transaction, Sammy retains ownership of 35,630 shares in the company. The company, currently valued at approximately $46 million in market capitalization, maintains strong liquidity with a current ratio of 5.05. For deeper insights into RBOT’s financial health and additional analysis, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Vicarious Surgical Inc. reported its Q1 2025 financial results, revealing a decrease in operating expenses and advancements in its surgical robotic systems. The company reported an adjusted net loss of $15.3 million, or $2.58 per share, while total operating expenses decreased by 2% compared to Q1 2024. R&D expenses were reduced to $9.4 million, while G&A expenses increased slightly to $5.3 million. Vicarious Surgical is progressing towards becoming a clinical-stage company in 2025, with plans for initial human clinical trials and regulatory approvals underway. The company is leveraging strategic partnerships, including a recent collaboration with UMass Memorial Medical (TASE:BLWV) Center, to optimize surgical workflows. Analysts from BTIG and TD Cowen have shown interest in the company’s cash management and supply chain capabilities, noting the importance of disciplined spending and the ability to manage complex supply chains effectively. Vicarious Surgical maintains a cash balance of $37 million and anticipates a full-year cash burn of $50 million. The company is evaluating financing options to support its development plans, with a focus on maintaining disciplined capital allocation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.